Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol

被引：83
|
作者：
Garg, Satish K. [1 ,2 ]
Peters, Anne L. [3 ]
Buse, John B. [4 ]
Danne, Thomas [5 ]
机构：
[1] Univ Colorado Denver, Sch Med, Dept Med & Pediat, Aurora, CO USA
[2] Barbara Davis Ctr Diabet, Aurora, CO USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[5] Hannover Med Sch, Childrens & Youth Hosp Bult, Hannover, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷 / 09期
关键词：
INSULIN; KETOACIDOSIS; DAPAGLIFLOZIN; CHILDREN; STATE;
D O I：
10.1089/dia.2018.0246
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：571 / 575
页数：5
相关论文
共 50 条
  • [41] Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
    Nazari, Somayeh
    Mirkhani, Hossein
    CURRENT DIABETES REVIEWS, 2023, 19 (08)
  • [42] Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
    Santos, Leyna Leite
    Camello De Lima, Fernando Jose
    De Sousa-Rodrigues, Celio Fernando
    Barbosa, Fabiano Timbo
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (07): : 636 - 641
  • [43] Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
    Siegmund, Thorsten
    Javier Ampudia-Blasco, Francisco
    Schnell, Oliver
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [44] International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
    Danne, Thomas
    Garg, Satish
    Peters, Anne L.
    Buse, John B.
    Mathieu, Chantal
    Pettus, Jeremy H.
    Alexander, Charles M.
    Battelino, Tadej
    Javier Ampudia-Blasco, F.
    Bode, Bruce W.
    Cariou, Bertrand
    Close, Kelly L.
    Dandona, Paresh
    Dutta, Sanjoy
    Ferrannini, Ele
    Fourlanos, Spiros
    Grunberger, George
    Heller, Simon R.
    Henry, Robert R.
    Kurian, Martin J.
    Kushner, Jake A.
    Oron, Tal
    Parkin, Christopher G.
    Pieber, Thomas R.
    Rodbard, Helena W.
    Schatz, Desmond
    Skyler, Jay S.
    Tamborlane, William V.
    Yokote, Koutaro
    Phillip, Moshe
    DIABETES CARE, 2019, 42 (06) : 1147 - 1154
  • [45] SGLT-2 Inhibitors and the Risk of Community-Acquired Pneumonia in Patients with Type-2 Diabetes
    Brunetti, Vanessa
    Reynier, Pauline
    Azoulay, Laurent
    Yu, Oriana H. Y.
    Ernst, Pierre
    Platt, Robert W.
    Filion, Kristian B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 37 - 38
  • [46] Cost of DKA treatment in children with type 1 diabetes varies by duration of diabetes and insurance status
    Rewers, A
    Maniatis, A
    Klingensmith, G
    Bothner, J
    DIABETES, 2004, 53 : A290 - A290
  • [47] SGLT INHIBITORS IN T1D: DKA RISK AND DKA RISK MITIGATION STRATEGIES, ESPECIALLY CGM-CKM, TO ENABLE THERAPY USE FOR HEART AND KIDNEY HEALTH
    Busui, R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A8 - A8
  • [48] SGLT2 Inhibitors in Type 2 Diabetes: comparatively higher Risk of Ketoacidosis
    Dobler, Gabriele
    DIABETOLOGIE UND STOFFWECHSEL, 2022, 17 (04) : 240 - 240
  • [49] Sleep Disturbances in Type 1 Diabetes and Mitigating Cardiovascular Risk
    Abu Irsheed, Ghada
    Martyn-Nemeth, Pamela
    Baron, Kelly Glazer
    Reutrakul, Sirimon
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (12): : 3011 - 3026
  • [50] SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
    Griffin, Tomas P.
    Dinneen, Sean F.
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (08) : JC40 - JC40
12345